You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
据报复星医药(02196.HK)不打算再於中国进行新型肺炎疫苗临床测试
阿思达克 11-04 15:35
据《路透》报道引述管理层报道,德国BioNTech的中国合作夥伴复星医药(02196.HK),不打算将已在中国完成早期试验的新型肺炎疫苗作进一步临床测试。

据报复星医药首席医学官回爱民表示,将聚焦於寻求中国批准BioNTech另一款实验疫苗,该疫苗正於美国进行最後阶段的人体试验。

另外,台湾传媒报道,台湾东洋日前取得BioNTech的新型肺炎疫苗在台销售的「有条件授权书」,但由於BioNTech与台湾卫福部对於疫苗的数量与价格仍谈不拢,因此宣布无法如期代理疫苗进口。台湾东洋指取得授权後,可就疫苗交货数量、时间、价格与台湾主管机关协商,但政府采购数量及价格上仍有落差,截至授权协商期满并未达成共识。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account